BioSpace News Archive

Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences.

Ocular Therapeutix, Inc. today announced that it has granted inducement equity awards to its newly appointed Executive Chairman, Pravin U. Dugel, MD and to its newly appointed Chief Strategy Officer, Sanjay Nayak, MBBS, PhD.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with inflammatory and renal diseases who have significant unmet medical needs, announces availability of a new white paper titled, “Inflammasome ASC Inhibitor IC 100, Promising Therapeutic Potential For Neurological Diseases.”

SeaStar Medical Holding Corporation (Nasdaq: ICU) announces that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) Approval Order to the Selective Cytopheretic Device (SCD) Pediatric (SCD-PED) for use in children weighing 10 kilograms or more with acute kidney injury (AKI) due to sepsis or a septic condition requiring kidney replacement therapy (KRT).

Rigel Pharmaceuticals, Inc. (“Rigel”) (Nasdaq: RIGL) today announced that it has entered into a definitive agreement to acquire the U.S. rights to GAVRETO® (pralsetinib) from Blueprint Medicines Corporation (“Blueprint”).

Soleno Therapeutics, Inc. today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the TD Cowen 44th Annual Healthcare Conference on Monday, March 4, 2024, at 1:30 PM Eastern Time.

OncoC4, Inc. (“OncoC4”) today announced that the first patient with metastatic castration resistant prostate cancer (“mCRPC”) has been dosed in a Phase 1/2 trial evaluating the anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart) in combination with radioligand therapy, lutetium (177Lu) vipivotide tetraxetan (Pluvicto®).

Artiva Biotherapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Artiva’s lead program AlloNK®.

Crown Laboratories, Inc., a leader in innovative skincare solutions, is thrilled to announce that its best-selling acne wash, PanOxyl®, has been named the #1 dermatologist recommended Benzoyl Peroxide brand.* A portfolio comprised of products that cleanse, manage, or moisturize acne-prone skin, PanOxyl is a go-to solution for millions of consumers across the country.

Coya Therapeutics, Inc. announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, will present data on its novel oxidative stress biomarker candidate from a large cohort of Amyotrophic Latera Sclerosis (ALS) patients at the upcoming Society of Neuroimmune Pharmacology Conference being held on March 10-13, 2024 in Charleston, SC.